Acesso livre
Acesso livre

Infectologia

Estudo randomizado | Imunoglobulinas intravenosas não melhoram os desfechos em pacientes com síndrome da angústia respiratória aguda moderada a grave associada a COVID-19.

16 Nov, 2021 | 12:47h

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine

 

Comentário no Twitter

 

Revisão | Trombocitopenia trombótica imune induzida por vacina.

16 Nov, 2021 | 12:46h

Vaccine-induced immune thrombotic thrombocytopenia – The Lancet Haematology

Conteúdos relacionados:

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

 

Comentário no Twitter

 

Covid: Áustria impõe lockdown a não vacinados.

16 Nov, 2021 | 12:44h

Covid: Austria introduces lockdown for unvaccinated – BBC

Ver também: Austria orders nationwide lockdown for the unvaccinated – Associated Press

Covid-19: produção global de vacinas é desordenada e a escassez é decorrente de outros fatores além da acumulação por alguns países.

16 Nov, 2021 | 12:43h

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding – The BMJ

 

Comentário no Twitter

 

Pílula da Pfizer é o mais recente tratamento contra COVID a se mostrar promissor.

16 Nov, 2021 | 12:41h

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation

Conteúdos relacionados:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Merck v Pfizer: como os dois antivirais contra COVID funcionam e serão utilizados.

16 Nov, 2021 | 12:38h

Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used – The Conversation

Conteúdos relacionados:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Estudo randomizado fase 4 | Administração de vacinas contra COVID-19 (AstraZeneca ou Pfizer) concomitantemente às vacinas contra influenza sazonal em adultos é segura e preserva a resposta imune de ambas as vacinas.

15 Nov, 2021 | 14:10h

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

Amplo estudo populacional mostra que infecção prévia por SARS-CoV-2 reduz o risco de infecção após vacina de mRNA.

15 Nov, 2021 | 14:08h

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar – JAMA

Comentários:

Vaccine plus previous infection may offer enhanced COVID-19 protection – CIDRAP

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination – News Medical

 

Comentário no Twitter

 

Estudo populacional no Catar mostrou que a efetividade contra doença grave, crítica ou fatal induzida pela variante Delta do SARS-CoV-2 foi de 93,4% para a vacina da Pfizer e de 96,1% para a vacina da Moderna.

15 Nov, 2021 | 14:06h

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar – Nature Medicine

 

Comentário no Twitter

 

[Preprint] Risco de COVID-19 grave é raro entre pessoas com vacinação plena na Inglaterra.

15 Nov, 2021 | 14:01h

Comentário: Risk of severe COVID-19 is rare among fully vaccinated individuals in England – News Medical

Estudo original: Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY – medRxiv

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.